Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 19468 | 439 | 35.6 | 80% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 232 | 19686 | TAMOXIFEN//AROMATASE INHIBITORS//ANASTROZOLE |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | ENDOXIFEN | Author keyword | 83 | 79% | 12% | 53 |
| 2 | DESMETHYLTAMOXIFEN | Author keyword | 9 | 83% | 1% | 5 |
| 3 | N DESMETHYL TAMOXIFEN | Author keyword | 6 | 100% | 1% | 4 |
| 4 | N DESMETHYLTAMOXIFEN | Author keyword | 5 | 60% | 1% | 6 |
| 5 | 4 HYDROXYTAMOXIFEN | Author keyword | 5 | 23% | 5% | 20 |
| 6 | CYP2D6 INHIBITOR | Author keyword | 4 | 75% | 1% | 3 |
| 7 | TAMOXIFEN N OXIDE | Author keyword | 3 | 100% | 1% | 3 |
| 8 | METABOLITE LEVELS | Author keyword | 2 | 44% | 1% | 4 |
| 9 | P450 2D6 | Author keyword | 2 | 44% | 1% | 4 |
| 10 | C10ORF11 | Author keyword | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | ENDOXIFEN | 83 | 79% | 12% | 53 | Search ENDOXIFEN | Search ENDOXIFEN |
| 2 | DESMETHYLTAMOXIFEN | 9 | 83% | 1% | 5 | Search DESMETHYLTAMOXIFEN | Search DESMETHYLTAMOXIFEN |
| 3 | N DESMETHYL TAMOXIFEN | 6 | 100% | 1% | 4 | Search N+DESMETHYL+TAMOXIFEN | Search N+DESMETHYL+TAMOXIFEN |
| 4 | N DESMETHYLTAMOXIFEN | 5 | 60% | 1% | 6 | Search N+DESMETHYLTAMOXIFEN | Search N+DESMETHYLTAMOXIFEN |
| 5 | 4 HYDROXYTAMOXIFEN | 5 | 23% | 5% | 20 | Search 4+HYDROXYTAMOXIFEN | Search 4+HYDROXYTAMOXIFEN |
| 6 | CYP2D6 INHIBITOR | 4 | 75% | 1% | 3 | Search CYP2D6+INHIBITOR | Search CYP2D6+INHIBITOR |
| 7 | TAMOXIFEN N OXIDE | 3 | 100% | 1% | 3 | Search TAMOXIFEN+N+OXIDE | Search TAMOXIFEN+N+OXIDE |
| 8 | METABOLITE LEVELS | 2 | 44% | 1% | 4 | Search METABOLITE+LEVELS | Search METABOLITE+LEVELS |
| 9 | P450 2D6 | 2 | 44% | 1% | 4 | Search P450+2D6 | Search P450+2D6 |
| 10 | C10ORF11 | 2 | 67% | 0% | 2 | Search C10ORF11 | Search C10ORF11 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | RECEIVING ADJUVANT TAMOXIFEN | 47 | 66% | 10% | 44 |
| 2 | ENDOXIFEN | 29 | 88% | 3% | 14 |
| 3 | CYP2D6 GENOTYPE | 29 | 33% | 16% | 72 |
| 4 | CYP2D6 ASTERISK 10 GENOTYPE | 24 | 91% | 2% | 10 |
| 5 | GROUP 1 98 TRIAL | 15 | 56% | 4% | 18 |
| 6 | UGT2B7 GENOTYPE | 12 | 75% | 2% | 9 |
| 7 | TAMOXIFEN METABOLISM | 12 | 44% | 5% | 20 |
| 8 | 4 HYDROXY N DESMETHYLTAMOXIFEN | 11 | 69% | 2% | 9 |
| 9 | CYP2D6 ASTERISK 10 | 10 | 44% | 4% | 17 |
| 10 | RE CYP2D6 | 8 | 75% | 1% | 6 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping | 2015 | 1 | 90 | 84% |
| CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis | 2013 | 6 | 55 | 75% |
| Pharmacogenetics of Endocrine Therapy for Breast Cancer | 2011 | 30 | 49 | 65% |
| Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis | 2010 | 26 | 32 | 81% |
| CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis | 2013 | 7 | 36 | 61% |
| Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy | 2014 | 3 | 87 | 61% |
| Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters | 2012 | 32 | 83 | 42% |
| CYP2D6 and tamoxifen: DNA matters in breast cancer | 2009 | 123 | 71 | 37% |
| Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment | 2012 | 6 | 18 | 72% |
| Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes | 2011 | 18 | 50 | 52% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | LSU STANLEY SCOTT CANC | 1 | 100% | 0.5% | 2 |
| 2 | BREAST ONCOL PROGRAM | 1 | 12% | 2.3% | 10 |
| 3 | ONKOZENTRUM | 1 | 40% | 0.5% | 2 |
| 4 | ANAL ORGAN | 1 | 50% | 0.2% | 1 |
| 5 | BREAST CANC CHAIR ONCOL | 1 | 50% | 0.2% | 1 |
| 6 | CANC 6312 | 1 | 50% | 0.2% | 1 |
| 7 | CLIN PHARMACOL EXPT THER EUT MED | 1 | 50% | 0.2% | 1 |
| 8 | DEP FARM HOSP | 1 | 50% | 0.2% | 1 |
| 9 | INVEST DRUG SECT | 1 | 50% | 0.2% | 1 |
| 10 | LHSC UNIV HOSP | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000236454 | TAMOXIFEN//TOREMIFENE//DROLOXIFENE |
| 2 | 0.0000199512 | AEBS//ANTIESTROGEN BINDING SITES//ANALOG II |
| 3 | 0.0000154644 | AROMATASE INHIBITORS//EXEMESTANE//ANASTROZOLE |
| 4 | 0.0000132230 | CYP2D6//DEBRISOQUINE//CYP2C19 |
| 5 | 0.0000099336 | RALOXIFENE//TISSUE SELECTIVE ESTROGEN COMPLEX//BAZEDOXIFENE |
| 6 | 0.0000090087 | ESTROGENIC RECRUITMENT//AMINOGLUTETHIMIDE//CYCLIC TREATMENT |
| 7 | 0.0000077197 | PHARMACOGENOMICS//PERSONALIZED MEDICINE//PROGRAM PERSONALIZED MED TARGETED THER EUT |
| 8 | 0.0000056918 | P450 ENZYME//ENZYMELESS BIOSENSORS//IRON TETRAPYRIDINOPORPHYRAZINE |
| 9 | 0.0000046424 | HS OS 1//BRM BIOLOGICAL RESPONSE MODIFIER//DIAGNOST RADIOL RADIAT ONCOL |
| 10 | 0.0000045878 | ESTROGEN RECEPTOR VARIANTS//JC HEUSON CANCEROL MAMMAIRE//SERV HISTOL CYTOL EXPT |